We established an enzalutamide-resistant C4-2b prostate cell line that has an active androgen receptor by maintaining the C4-2b cell line in serially increasing concentrations of enzalutamide. Among the CRPC cell lines, we selected the C4-2b cell line because it is known to have AR variants, and we desired to identify enzymes with the ability to regulate the activity of AR variants as well as the wild type AR. After 2 months, we acquired resistant cells in even 10 uM enzalutamide. After validation of enzalutamide-resistant character, we analyzed global changes in mRNA expression by using quantitative mRNA-sequencing analysis. SOURCE: Kyoung-Hwa Lee (lee12042@snu.ac.kr) -  Seoul National University Hospital

Pluto Bioinformatics

GSE110802: High-throughput profiling of mRNA from parental and Enzalutamide resistant C4-2b prostate cancer cell lines